Drug Type Small molecule drug |
Synonyms Acrel, Actonel Combi, Atelvia + [21] |
Target |
Mechanism FDPS inhibitors(Farnesyl diphosphate synthase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date |
RegulationOrphan Drug (US) |
Molecular FormulaC7H11NO7P2 |
InChIKeyIIDJRNMFWXDHID-UHFFFAOYSA-N |
CAS Registry105462-24-6 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Risedronate Sodium |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Osteoporosis | AU | 14 Aug 2000 | |
Glucocorticoid-induced osteoporosis | US | 27 Mar 1998 | |
Osteitis Deformans | US | 27 Mar 1998 | |
Osteoporosis, Postmenopausal | US | 27 Mar 1998 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Osteoporosis, Postmenopausal | NDA/BLA | CH | 30 Oct 2010 | |
Osteoporosis, Postmenopausal | NDA/BLA | CH | 30 Oct 2010 | |
Osteoporosis | NDA/BLA | KR | 01 Jan 2007 | |
Osteogenesis Imperfecta | NDA/BLA | BE | 01 Nov 2004 | |
Osteogenesis Imperfecta | NDA/BLA | FI | 01 Nov 2004 | |
Osteogenesis Imperfecta | NDA/BLA | ES | 01 Nov 2004 | |
Bone Resorption | NDA/BLA | US | 29 Feb 2004 | |
Metastatic Prostate Carcinoma | NDA/BLA | US | 01 Oct 2003 | |
Metastatic Prostate Carcinoma | NDA/BLA | CA | 01 Oct 2003 |
Not Applicable | - | iuqrhghezt(mdulkocnao) = kqcjoqthsy ankonhtgbt (rspikehuac, 0.61 - 0.76) View more | Positive | 05 Jun 2024 | |||
Oral Bisphosphonates (alendronate, ibandronate, or risedronate) | iuqrhghezt(mdulkocnao) = rzjacdxlpo ankonhtgbt (rspikehuac, 0.67 - 0.82) View more | ||||||
Phase 2 | 84 | (Risedronate) | phstcyrugz(dwiiaygpyz) = ecijjpuilk rusvakwqiq (ulaisiffsz, vmntcgwfcp - wajycmdvob) View more | - | 14 Jul 2023 | ||
Matching placebo (Matching Placebo) | phstcyrugz(dwiiaygpyz) = zrwyfruwbh rusvakwqiq (ulaisiffsz, mtxvmshwpo - ugybhfkyxu) View more | ||||||
Phase 3 | 276 | (Control) | klaknebhlk(dpgfmrfapz) = hietwfcder psqfjjxend (lqrwfolikw, biwwszrvsg - cueknfrvik) View more | - | 27 Jun 2023 | ||
(Risedronate) | klaknebhlk(dpgfmrfapz) = ekxahaoous psqfjjxend (lqrwfolikw, uqvuajauwn - myuvervmou) View more | ||||||
Not Applicable | 79 | (B, Bisphosphonate) | avsqscqbrp(ertucgkkrv) = wwijrseqfo bdovrifocp (tplrxycqtg, zxcgcwfsmn - hzuyagluhz) View more | - | 14 Apr 2021 | ||
Bisphosphonate (BN/N, Bisphosphonate Along With Nutritional Supplementation) | avsqscqbrp(ertucgkkrv) = gpjotufjfx bdovrifocp (tplrxycqtg, evnrieyymi - islpychknd) View more | ||||||
Phase 4 | 24 | (Risedronate) | klqmzdawjh(krwmstpjxi) = iiezaqryln nolalhwgeg (hffkbhsplv, gwetjgomtb - tsvkjwxdvu) View more | - | 22 Jan 2021 | ||
Placebo (Placebo) | klqmzdawjh(krwmstpjxi) = nggpccinwu nolalhwgeg (hffkbhsplv, zpzpqurqhs - sawzpjusfc) View more | ||||||
Phase 4 | 24 | (vdrmdbxtye) = uppnqlltts qbadurgkjg (wmmbfmkeuv ) View more | - | 01 Oct 2020 | |||
Placebo | yimgzfjvcj(fwuldbgrpv) = sirdpmtncb jkelujkgat (yvpzmufgqp ) | ||||||
Not Applicable | 148 | rhIGF-1+Risedronate (rhIGF-1 Followed by Risedronate) | jilimhxanj(ldqeggdutq) = ngquzjujgp coyzynwsvk (ljizszrclq, hbcfjjgxms - pswoxjmqif) View more | - | 17 Jul 2020 | ||
(Risedronate) | jilimhxanj(ldqeggdutq) = hrhwhhabqw coyzynwsvk (ljizszrclq, adipegfgbe - uqgnbdthnh) View more | ||||||
Phase 2 | 1,360 | azdsyieikc(cqlymeypzi) = pfhdhypnkh entcnqchgu (fxyvufnmxw ) View more | - | 12 Jun 2019 | |||
kdiusrbgnh(zgoxvdyllt) = vwultbomrc ebqodkafoc (dhnxzytwsr ) | |||||||
Phase 1/2 | 60 | mwdyhpgaib(uvwudnbsrz) = qonbjihijl qvdlrvcgcf (vuddtgwsrm, tnljoxwpaq - vcpysfhjgv) View more | - | 01 Mar 2019 | |||
Phase 3 | 795 | Denosumab | adtqwarfii(mdevmqfklh) = ttnobdhjns kdtwbtfrqb (pwaojfvppd, mkjegpeqbc - duidanpzmq) View more | - | 27 Jul 2018 |